Piper Sandler analyst David Amsellem raised the firm’s price target on AbbVie (ABBV) to $289 from $284 and keeps an Overweight rating on the shares following quarterly results. The firm cites higher Skyrizi estimates in 2026-plus and higher estimates for key products in the Neuroscience segment, which it believes remains a largely under-the-radar business.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: